XTalks

MAY 11, 2023

Clinical trials are essential for the development of new treatments for rare diseases, but they can be complex and challenging to execute. I’m interested to learn more about the history of rare disease trials as it relates to the patient voice. Wendy: I do think it varies significantly from place to place.

Clinical Trials 97

Clinical Trials Clinical Trials Trials Development 97

pharmaphorum

JULY 7, 2022

Eradicating cancer is an ambitious goal for oncologists and life science companies around the world. But, with a growing number of cancer treatments entering the market each year and dedicated research efforts driving innovation in the sector, there are positive signs that the industry is on the right track.

Vaccination 52

Vaccination Vaccine Life Science Trials 52

pharmaphorum

JANUARY 24, 2022

Francisco Partners is picking up a range of databases and analytics tools – including Health Insights, MarketScan, Clinical Development, Social Programme Management, Micromedex and other imaging and radiology tools – for an undisclosed sum estimated to be in the region of $1 billion.

Radiology 111

Radiology Marketing Genome Genomics 111

pharmaphorum

DECEMBER 21, 2021

Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene. Pharma companies are looking at whether blocking TIGIT as well as PD-1/PD-L1 can improve the efficacy of cancer immunotherapy.

Drugs 98

Drugs Antibody Pharma Companies Development 98

Delveinsight

AUGUST 2, 2020

The dynamics of the cancer cachexia market is expected to gain momentum as several companies are testing the waters, advancing cancer cachexia pipeline. The company is currently preparing for further clinical trials in cachexia in Non-Small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC).

Marketing 94

Marketing Pharma Companies Development Hormones 94

XTalks

MARCH 28, 2024

The FDA’s approval of Duvyzat for DMD, based on our robust and successful clinical development program, reflects Italfarmaco’s commitment to providing a safe and proven-effective therapy that can have a meaningful impact for people living with DMD,” said Paolo Bettica, MD, PhD, chief medical officer at Italfarmaco Group in a press release.

FDA Approval 105

FDA Approval Genetics Gene Therapy Gene 105

Pharmaceutical Technology

JUNE 15, 2023

AI in pharma R&D is one of the latest innovations helping teams apply existing knowledge to new problems. Artificial intelligence (AI) has many implications for pharmaceutical companies, including on research, drug discovery and development, manufacturing and trials.

Pharma R&D 130

Pharma R&D Production Manufacturing Development 130

pharmaphorum

JULY 5, 2021

The handover comes four years after Pamplona Capital Management bought the company for around $5 billion, and just a few weeks after lab tech company Thermo Fisher Scientific agreed to acquire another CRO – PPD – in a deal valued at $17.4

Clinical Trials 64

Clinical Trials Clinical Trials Regulation Trials 64

Drug Discovery World

MAY 6, 2024

billion on R&D during 2021, with Germany and Switzerland being the biggest contributors, and around one fourth of clinical trials worldwide were performed in Europe 1. During the period 2016-2021, the Brazilian, Chinese and Indian markets grew by 11.7%, 6.7% respectively compared to an average market growth of 5.8%

Drugs 59

Drugs Life Science Gene Editing Gene 59

pharmaphorum

JULY 1, 2021

Merck and its partners are hoping to have initial data from trials of the bioelectronic device by the end of 2022 , which will then be used to establish a clinical development plan with an eye on getting approvals in major markets like Europe and the US.

Drug Delivery 94

Drug Delivery Pharma Companies Clinical Development Development 94

pharmaphorum

JUNE 8, 2021

Dr Jay Mei from Antengene tells us how the Asia Pacific region is opening up to innovative pharma companies, and gives tips for companies navigating this enormous market. At the same time, lots of people with experience at multinational pharmaceutical companies have chosen to return home.

Marketing 105

Marketing Drugs Regulation Development 105

pharmaphorum

APRIL 28, 2022

Although they have, by definition, small addressable markets, the treatments cost just as many resources to develop as therapies for more common diseases – sometimes more, because of the added difficulty of finding sufficiently large patient populations for trials and finding disease experts to run them. So that is the trick.

Pharma Companies 59

Pharma Companies Branding Development Marketing 59

The Pharma Data

SEPTEMBER 11, 2020

In an effort to slow the spread of the disease and prevent a second wave, pharma companies around the world are continuously looking to advance new methods of treatment. This week’s round up dives into developments from companies based in Australia and the US. Saama Technologies, Inc. , Source link.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Drug Delivery 52

pharmaphorum

DECEMBER 23, 2020

The American Society of Clinical Oncology (ASCO) annual conference was one of the highlights of the year in cancer research and the fact it was held virtually did not distract from some stunning clinical lung cancer trial results presented by AstraZeneca. months, compared with 6.7 months in patients treated with chemotherapy.

Marketing 96

Marketing Gene Silencing Gene Drugs 96

Drug Discovery World

MARCH 29, 2023

Regulatory data protection (RDP) period RDP refers to the time when generic drug makers cannot refer to an innovator drug’s data to obtain a marketing authorisation 2. According to EFPIA, RDP protects an innovator’s investment by granting a limited period of exclusivity on the data it generated, starting from marketing authorisation 4.

Clinical Trials 52

Clinical Trials Clinical Trials Production Medicine 52

pharmaphorum

NOVEMBER 23, 2021

GSK gets worldwide rights to the potentially first-in-class drug, with the exception of China, and will be wholly responsible in its markets for clinical development and commercialisation. Preliminary data has shown that the drug can reduce levels of HSD17B13 protein as well as other liver enzymes that are biomarkers for NASH.

Sales 52

Sales Drugs Trials RNA 52

pharmaphorum

DECEMBER 15, 2021

Dialogue requires humility on the drug company’s side—accepting that sometimes we are wrong about matters we think we understand—and trust on the patients’ side that representatives of large, for-profit entities really have come to listen. Previously, Anthony served as the Global Head of Patient Insights, Solutions and Outcomes at Sanofi.

Pharma Companies 145

Pharma Companies Development Medicine Clinical Trials 145

Delveinsight

AUGUST 24, 2020

The launch of the Pipeline therapies, increasing EPI prevalence shall fuel the Exocrine pancreatic insufficiency market size estimated to be approximately USD 1,695.26 However, the main pharmacologic treatment and the mainstay in the Exocrine pancreatic insufficiency market is Pancreatic enzyme replacement therapy (PERT).

Marketing 52

Marketing Production Pharma Companies Containment 52

pharmaphorum

DECEMBER 2, 2020

Their follow-up to penicillin, Terramycin, first marketed in 1950, was both their first proprietary drug, and the first for which the company used sales reps, their soon to be formidable force of salesmen starting with just eight members. Likewise, tanezumab, an anti-osteoarthritic, failed in trials.

Sales 128

Sales Production Drugs Marketing 128

pharmaphorum

MAY 14, 2021

In an interview with pharmaphorum’s news editor Richard Staines, chief operating officer Arnout Ploos van Amstel revealed how the biotech and its “mystery CEO” managed to swoop for the drug ahead of big pharma rivals. It’s extremely possible a pharma company may want to partner and it can have many forms.

Licensing 66

Licensing Licensing Drugs Marketing 66

Delveinsight

AUGUST 4, 2021

Similarly, many clinical trials are going on to further strengthen the therapeutic pipeline for different Neurological Conditions. Several therapies have been approved in the Epilepsy Market. Similarly, other companies in the domain such as Eisai/ BioArctic AB, Hoffmann-La Roche/Chugai Pharmaceuticals, Anavex Life Sciences Corp.,

Marketing 98

Marketing Genetics Development Clinical Development 98

Drug Discovery World

OCTOBER 4, 2022

million from the National Institute on Aging of the National Institutes of Health, the company plans to begin a Phase Ia clinical trial evaluating its lead tau self- association small molecule inhibitor OLX-07010. . Several of the large pharma companies have recently re-entered the dementia field.

Development 52

Development In-Vivo Compound Screening Clinical Development 52

pharmaphorum

SEPTEMBER 29, 2020

As a result of this shift in drug development, a highly concentrated overlay in product modalities and mechanisms of action has crowded the oncology pipeline across a very broad range of hematological and solid tumour indications. Case Study: From Technology Agreement to co-development and co-commercialisation partnership.

Research 132

Research Gene Editing Gene Development 132

Delveinsight

JULY 29, 2020

The situation worldwide was so serious that the whole nation was put under lockdown from 25 March 2020, all the flights were cancelled, public transportation was ceased, companies were shut and markets were closed down. The first part of Phase-1 trials commenced at PGIMS, Rohtak on July 17. Zydus Cadila ( ZyCoV-D ).

Vaccination 62

Vaccination Vaccine Clinical Trials Clinical Trials 62

Drug Discovery World

OCTOBER 16, 2023

Despite the overall reduction in major pharma R&D centres in the UK, global pharma companies continue to engage with academic and biotech organisations here, particularly in hotspots such as the Golden Triangle, the Northwest, and Scotland, through the strong networks that have been developed between these organisations.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

pharmaphorum

OCTOBER 26, 2022

For example, at the SSIEM Annual Symposium earlier this month, the company shared data on a new candidate for the treatment of Fabry disease, a rare genetic blood disorder. Chiesi’s approach to these trials presents a clear demonstration of Chiesi’s patient-centricity approach in action. Caring for a global community.

Development 96

Development Trials Marketing Life Science 96

pharmaphorum

FEBRUARY 18, 2021

After a year in which the need for digital transformation in pharma reached white heat levels, the sector mustn’t cool off in 2021 and revert to business-as-usual. A return to normal is the longed for goal for many of us, but pharma companies must decide what their future normal should look like. years and $2.5

Medicine 109

Medicine Pharma Companies Clinical Trials Clinical Trials 109

Drug Discovery World

OCTOBER 4, 2022

There’s no question that cell and gene therapies have emerged as some of the most promising and innovative medicines on the market. . With 3,633 advanced therapeutical medicinal products (ATMPs) currently in some form of clinical or pre- clinical development, the sector shows no signs of slowing down.

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

Pharma Marketing Network

JUNE 8, 2020

Don (PMN): Hi good morning everyone, welcome to the pharma marketing podcast. My background for decades now is in the pharma marketing and branding space, working with all sorts of pharma products, devices, diagnostics. Do you connect patients with the clinical trial folks? Don (PMN): Wonderful.

Doctors 40

Doctors Doctor Clinical Trials Clinical Trials 40

pharmaphorum

APRIL 7, 2021

Under the leadership of CEO Jan van de Winkel it has gone from financially precarious position following the stock market crash in the late noughties, to the darling of the Nasdaq with a US IPO of more than $500 million in 2019. Clinical trials are slower to run and complete because hospitals are busy with COVID-19 cases.

Antibody 91

Antibody Life Science Development Regulation 91

Delveinsight

NOVEMBER 29, 2020

Recent years started witnessing the emergence of novel treatment approaches that have been keeping the Retinal vein occlusion market in a hyped-up state. Looking at the potential of the pipeline therapies they hold once approved, pharmaceutical companies are charting out a seemingly exciting course in the market.

Marketing 52

Marketing Pharma Companies Drug Delivery Clinical Trials 52

Delveinsight

AUGUST 25, 2021

Pharmaceutical companies may deal in both generic and brand-name drugs as well as medical devices. They are governed by a number of rules and regulations that govern drug patenting, testing, safety, efficacy, and marketing. . There are 23 therapies and vaccines in total that are in Phase II of clinical trials.

Vaccination 98

Vaccination Vaccine Sales Drugs 98

pharmaphorum

APRIL 19, 2021

It’s been made possible by an all-hands-on-deck approach from the NHS, academia, regulators and other players in the health system who have worked together to produce clinical data on vaccines and therapies for COVID-19. If you look at the development we signed 15,000 people in six weeks in a trial set up by the NHS.

Vaccination 98

Vaccination Vaccine Life Science Antibody 98

pharmaphorum

AUGUST 4, 2020

AstraZeneca has bought an exclusive global licence to develop and market RXC006, a porcupine inhibitor for fibrotic diseases including idiopathic pulmonary fibrosis (IPF). Redx will receive up to $17m in early payments between signing the deal and the successful start of the first clinical trial.

Drugs 109

Drugs Clinical Trials Clinical Trials Pharma Companies 109

Pharmaceutical Technology

NOVEMBER 25, 2022

In many cases, pharma companies select a contract development and manufacturing organisation (CDMO) to develop products versus doing the work themselves for reasons related to cost, convenience, and capacity. Faster to market. The differences between adult and paediatric dosage forms are typically significant.

Manufacturing 130

Manufacturing Production Pharma Companies Development 130

pharmaphorum

MAY 21, 2021

Arecor Therapeutics is planning to float on the London stock market, to raise funding and awareness for its developmental portfolio of biologic drugs, which are based on already-marketed drugs reformulated to provide extra benefits for patients. . This is an evolution, we are going to the public market to grow a sustainable business.”.

Insulin 52

Insulin Drugs Production Marketing 52

Delveinsight

FEBRUARY 2, 2021

It is the only approved drug available in the NMOSD market. Thus, the news of its acquisition does not surprise as a horde of pharma giants would be keeping a keen eye on its activities. The Viela Bio acquisition will add four therapeutic candidates currently in nine development programs to the Horizon’s portfolio.

Drugs 40

Drugs Clinical Trials Clinical Trials Development 40